VIVS
VivoSim Labs, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.28
−0.29%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 112.0K | 131.0K | 144.0K | 109.0K | 370.0K |
| Cost of Revenue | 263.0K | — | 5.0K | — | — |
| Gross Profit | (151.0K) | 131.0K | 139.0K | 109.0K | 370.0K |
| Operating Expenses | |||||
| R&D Expense | 4.3M | 4.2M | 5.0M | 5.5M | 8.9M |
| SG&A Expense | 6.9M | 7.2M | 7.7M | 9.6M | 9.1M |
| General & Admin Expense | 6.9M | 7.2M | 7.7M | 9.6M | 9.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (5.0K) | — | 39.0K | 53.0K | 128.0K |
| Total Operating Expenses | 11.2M | 11.4M | 12.8M | 15.2M | 18.1M |
| Cost and Expenses | 11.4M | 11.4M | 12.8M | 15.2M | 18.1M |
| Operating Income (EBIT) | (11.3M) | (11.2M) | (12.6M) | (15.1M) | (17.7M) |
| Non-Operating | |||||
| Interest Income | 219.0K | 267.0K | 140.0K | 405.0K | 454.0K |
| Interest Expense | 12.0K | 12.0K | 10.0K | — | — |
| Net Interest Income | 207.0K | 255.0K | 130.0K | 405.0K | 454.0K |
| Other Non-Op Income/Expense | (1.0M) | (2.4M) | 10.1M | 417.0K | 474.0K |
| Non-Operating Income (excl Interest) | 990.0K | 2.3M | (10.1M) | (417.0K) | (474.0K) |
| EBT (Pre-Tax Income) | (12.3M) | (13.6M) | (2.5M) | (14.7M) | (17.3M) |
| Income Tax Expense | 5.0K | (2.0K) | 2.0K | 2.0K | 2.0K |
| Bottom Line | |||||
| Net Income | (12.3M) | (13.8M) | (2.5M) | (14.7M) | (17.3M) |
| Earnings from Cont. Ops | (12.3M) | (13.6M) | (2.5M) | (14.7M) | (17.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (12.3M) | (13.8M) | (2.5M) | (14.7M) | (17.3M) |
| Per Share | |||||
| Basic EPS | ($6.04) | ($5.35) | ($1.70) | ($19.25) | ($23.77) |
| Diluted EPS | ($6.04) | ($5.35) | ($1.70) | ($19.25) | ($23.77) |
| Revenue Per Share | $0.02 | $0.05 | $0.10 | $0.14 | $0.51 |
| Shares | |||||
| Basic Shares Outstanding | 5.2M | 2.6M | 1.5M | 762076 | 726085 |
| Diluted Shares Outstanding | 5.2M | 2.6M | 1.5M | 762076 | 726085 |
| Profitability Metrics | |||||
| EBITDA | (12.1M) | (13.6M) | (2.2M) | (14.4M) | (17.0M) |
| D&A | 194.0K | — | 266.0K | 280.0K | 293.0K |
| EBIT | (12.3M) | (13.6M) | (2.5M) | (14.7M) | (17.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026